NCT07100782View on ClinicalTrials.gov

Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain

PHASE3RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

September 30, 2028

Conditions
EndometriosisPelvic Pain
Interventions
DRUG

Relugolix CT

Study medication will be provided by Sumitomo in pill bottles containing an 84-day supply of relugolix 40mg, estradiol 1mg, norethindrone acetate 0.5mg (Relugolix Combination therapy).

Trial Locations (1)

48109

RECRUITING

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of Michigan

OTHER